litlas
Log inCreate account

Robert Knight

Active 1996–2024

57
Papers
19,214
Citations
47
h-index
53
i10-index

Citations

Citations per year for Robert Knight1948: 2 citations1989: 2 citations1996: 7 citations1997: 27 citations1998: 44 citations1999: 26 citations2000: 56 citations2001: 96 citations2002: 72 citations2003: 104 citations2004: 88 citations2005: 76 citations2006: 110 citations2007: 164 citations2008: 168 citations2009: 275 citations2010: 234 citations2011: 249 citations2012: 152 citations2013: 194 citations2014: 129 citations2015: 131 citations2016: 154 citations2017: 135 citations2018: 121 citations2019: 439 citations2020: 473 citations2021: 370 citations2022: 279 citations2023: 144 citations2024: 219 citations2025: 81 citations2026: 1 citations1949–1988: no citations, so these years are not shown1990–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,743 citing papers, 29.9% of this breakdownUnited Kingdom: 385 citing papers, 6.6% of this breakdownGermany: 372 citing papers, 6.4% of this breakdownItaly: 371 citing papers, 6.4% of this breakdownFrance: 321 citing papers, 5.5% of this breakdownSpain: 228 citing papers, 3.9% of this breakdownCanada: 213 citing papers, 3.6% of this breakdownChina: 193 citing papers, 3.3% of this breakdownNetherlands: 170 citing papers, 2.9% of this breakdownSwitzerland: 158 citing papers, 2.7% of this breakdownAustralia: 156 citing papers, 2.7% of this breakdownGreece: 139 citing papers, 2.4% of this breakdown
0%29.9%Other 23.7%

Institutions

Fields

  • Medicine79.4%
  • Biochemistry, Genetics and Molecular Biology16%
  • Immunology and Microbiology1.4%
  • Computer Science1.1%
  • Neuroscience0.3%
  • Pharmacology, Toxicology and Pharmaceutics0.3%
  • Other1.5%

Topics

  • Multiple Myeloma Research and Treatments13%
  • Acute Myeloid Leukemia Research8.4%
  • Protein Degradation and Inhibitors7.9%
  • Bone health and treatments5%
  • Peptidase Inhibition and Analysis3.3%
  • Cancer Treatment and Pharmacology3.2%
  • Other59.2%

Coauthors

All papers

Open in search
  1. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

    Authors: Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert H. Collins, Manish R. Patel, Arthur E. Frankel, Anthony S. Stein, Mikkael A. Sekeres, Ronan Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert Knight, Katharine Yen, Sam Agresta, Stéphane de Botton, Martin S. Tallman - Blood 2017 cited by 1,469

  2. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

    Authors: Philip L. McCarthy, Sarah A. Holstein, Maria Teresa Petrucci, Paul G. Richardson, Cyrille Hulin, Patrizia Tosi, Sara Bringhen, Pellegrino Musto, Kenneth C. Anderson, D. Caillot, Francesca Gay, Philippe Moreau, Gérald Marit, Sin‐Ho Jung, Zhinuan Yu, Benjamin Winograd, Robert Knight, Antonio Palumbo, Michel Attal - Journal of Clinical Oncology 2017 cited by 679

  3. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

    Authors: Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michèle Cavo, Antonello Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon - New England Journal of Medicine 2014 cited by 786

  4. HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery

    Authors: Steven C. Katz, Ashley Moody, Prajna Guha, John C. Hardaway, Ethan Prince, Jason LaPorte, Mirela Stancu, Jill E. Slansky, Kimberly R. Jordan, Richard D. Schulick, Robert Knight, Abdul Saied, Vincent Armenio, Richard P. Junghans - Journal for ImmunoTherapy of Cancer 2020 cited by 79

  5. Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

    Authors: Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Deborah A. Thomas, Richard M. Stone, Craig B. Reeder, Kenton Wride, John Patin, M. Schmidt, Jerome B. Zeldis, Robert Knight - New England Journal of Medicine 2006 cited by 1,317

  6. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Authors: Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight - New England Journal of Medicine 2007 cited by 1,458

  7. Efficacy of Lenalidomide in Myelodysplastic Syndromes

    Authors: Alan F. List, S. Kurtin, Denise J. Roe, Andrew J. Buresh, Daruka Mahadevan, Deborah Fuchs, Lisa M. Rimsza, Ruth Heaton, Robert Knight, Jerome B. Zeldis - New England Journal of Medicine 2005 cited by 876

  8. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Authors: Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, Odile Beyne‐Rauzy, Ghulam Mufti, Moshe Mittelman, Petra Muus, Peter A.W. te Boekhorst, Guillermo Sanz, Consuelo del Cañizo, Agnès Guerci‐Bresler, Lars Nilsson, Uwe Platzbecker, Michael Lübbert, Bruno Quesnel, Mario Cazzola, Arnold Ganser, David Bowen, Brigitte Schlegelberger, Carlo Aul, Robert Knight, John Francis, Tommy Fu, Eva Hellström‐Lindberg, for the MDS-004 Lenalidomide del5q Study Group - Blood 2011 cited by 480

  9. Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    Authors: Donna M. Weber, Christine Chen, Rubén Niesvizky, Michael Wang, Andrew R. Belch, Edward A. Stadtmauer, David S. Siegel, Ivan Borrello, S. Vincent Rajkumar, Asher Chanan‐Khan, Sagar Lonial, Zhinuan Yu, John Patin, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight - New England Journal of Medicine 2007 cited by 1,235

  10. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

    Authors: Paul G. Richardson, Edie Weller, Sagar Lonial, Andrzej Jakubowiak, Sundar Jagannath, Noopur Raje, David Avigan, Wanling Xie, Irene M. Ghobrial, Robert Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Robin Joyce, Jonathan L. Kaufman, Deborah Doss, Diane Warren, Laura Lunde, Sarah Kaster, Carol Delaney, Teru Hideshima, Constantine S. Mitsiades, Robert Knight, Dixie‐Lee Esseltine, Kenneth C. Anderson - Blood 2010 cited by 862

  11. Sotatercept in patients with osteolytic lesions of multiple myeloma

    Authors: Abdulkadyrov Km, Galina Salogub, Nuriet K. Khuazheva, Matthew L. Sherman, Abderrahmane Laadem, Rachel Barger, Robert Knight, Shankar Srinivasan, Evangelos Terpos - British Journal of Haematology 2014 cited by 127

  12. Expression of multiple slow myosin heavy chain genes reveals a diversity of zebrafish slow twitch muscle fibres with differing requirements for Hedgehog and Prdm1 activity

    Authors: Stone Elworthy, Murray Hargrave, Robert Knight, Katharina Mebus, Philip W. Ingham - Development 2008 cited by 153

  13. Myofiber stretch induces tensile and shear deformation of muscle stem cells in their native niche

    Authors: Mohammad Haroon, Jenneke Klein‐Nulend, Astrid D. Bakker, Jianfeng Jin, Hadi Seddiqi, Carla Offringa, Gerard M.J. de Wit, Fabien Le Grand, Lorenzo Giordani, Karen Liu, Robert Knight, Richard T. Jaspers - Biophysical Journal 2021 cited by 32

  14. Systems Analysis Reveals Ageing-Related Perturbations in Retinoids and Sex Hormones in Alzheimer’s and Parkinson’s Diseases

    Authors: Simon Lam, Nils Hartmann, Rui Benfeitas, Cheng Zhang, Muhammad Arif, Hasan Türkez, Mathias Uhlén, Christoph Englert, Robert Knight, Adil Mardinoğlu - Biomedicines 2021 cited by 24

  15. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

    Authors: James R. Berenson, Alan Lichtenstein, Lisa A. Porter, Meletios Α. Dimopoulos, Rodolfo Bordoni, Saby George, Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hillary Blacklock, R. Bell, Joseph F. Simeone, Dirk J. Reitsma, M Heffernan, John J. Seaman, Robert Knight - Journal of Clinical Oncology 1998 cited by 653

  16. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

    Authors: Meletios Α. Dimopoulos, Christine Chen, Andrew Spencer, Rubén Niesvizky, Michel Attal, Edward A. Stadtmauer, Maria Teresa Petrucci, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, D. Weber - Leukemia 2009 cited by 360

  17. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

    Authors: S. Vincent Rajkumar, Laura Rosiñol, Mohamad A. Hussein, John Catalano, W Wiktor-Jędrzejczak, Lela M. Lucy, Marta Olesnyckyj, Zhinuan Yu, Robert Knight, Jerome B. Zeldis, Joan Bladé - Journal of Clinical Oncology 2008 cited by 345

  18. Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

    Authors: Stephen Schey, Paul Fields, J. Blake Bartlett, Ian Clarke, G. Ashan, Robert Knight, Matthew Streetly, Angus Dalgleish - Journal of Clinical Oncology 2004 cited by 313

  19. Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution

    Authors: Trevor L. Hoffman, Anna L. Javier, Shelley Campeau, Robert Knight, Thomas F. Schilling - Journal of Experimental Zoology Part B Molecular and Developmental Evolution 2007 cited by 125

  20. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

    Authors: on behalf of the MDS-003 Study Investigators, Alan F. List, John M. Bennett, Mikkael A. Sekeres, B. Skikne, Tommy Fu, Jamile M. Shammo, Stephen D. Nimer, Robert Knight, Aristoteles Giagounidis - Leukemia 2013 cited by 99

  21. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

    Authors: Paul G. Richardson, Emily Blood, Constantine S. Mitsiades, Sundar Jagannath, Steven R. Zeldenrust, Melissa Alsina, Robert Schlossman, S. Vincent Rajkumar, K.R. Desikan, Teru Hideshima, Nikhil C. Munshi, Kathleen Kelly-Colson, Deborah Doss, Mary McKenney, Svetlana G. Gorelik, Diane Warren, Andrea Freeman, Rebecca L. Rich, Anfang Wu, Marta Olesnyckyj, Kenton Wride, William S. Dalton, Jerome B. Zeldis, Robert Knight, Edie Weller, Kenneth C. Anderson - Blood 2006 cited by 522

  22. lockjawencodes a zebrafishtfap2arequired for early neural crest development

    Authors: Robert Knight, Sreelaja Nair, Sarah Nelson, Ali Afshar, Yashar Javidan, Robert Geisler, Gerd-Joerg Rauch, Thomas F. Schilling - Development 2003 cited by 194

  23. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

    Authors: Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Melissa Alsina, Irene M. Ghobrial, Robert Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura Lunde, John Feather, Michelle E. Maglio, Diane Warren, Dixil Francis, Teru Hideshima, Robert Knight, Dixie‐Lee Esseltine, Constantine S. Mitsiades, Edie Weller, Kenneth C. Anderson - Blood 2014 cited by 183

  24. Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

    Authors: Paul G. Richardson, Edie Weller, Sundar Jagannath, David Avigan, Melissa Alsina, Robert Schlossman, Amitabha Mazumder, Nikhil C. Munshi, Irene M. Ghobrial, Deborah Doss, Diane Warren, Laura Lunde, Mary McKenney, Carol Delaney, Constantine Mitsiades, Teru Hideshima, William S. Dalton, Robert Knight, Dixie‐Lee Esseltine, Kenneth C. Anderson - Journal of Clinical Oncology 2009 cited by 162